Your browser doesn't support javascript.
loading
LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression.
Liang, Yi; Ahmed, Musaddeque; Guo, Haiyang; Soares, Fraser; Hua, Junjie T; Gao, Shuai; Lu, Catherine; Poon, Christine; Han, Wanting; Langstein, Jens; Ekram, Muhammad B; Li, Brian; Davicioni, Elai; Takhar, Mandeep; Erho, Nicholas; Karnes, R Jeffrey; Chadwick, Dianne; van der Kwast, Theodorus; Boutros, Paul C; Arrowsmith, Cheryl H; Feng, Felix Y; Joshua, Anthony M; Zoubeidi, Amina; Cai, Changmeng; He, Housheng H.
Affiliation
  • Liang Y; Princess Margaret Cancer Centre/University Health Network, Toronto, Ontario, Canada.
  • Ahmed M; Princess Margaret Cancer Centre/University Health Network, Toronto, Ontario, Canada.
  • Guo H; Princess Margaret Cancer Centre/University Health Network, Toronto, Ontario, Canada.
  • Soares F; Princess Margaret Cancer Centre/University Health Network, Toronto, Ontario, Canada.
  • Hua JT; Princess Margaret Cancer Centre/University Health Network, Toronto, Ontario, Canada.
  • Gao S; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
  • Lu C; Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts.
  • Poon C; Princess Margaret Cancer Centre/University Health Network, Toronto, Ontario, Canada.
  • Han W; Princess Margaret Cancer Centre/University Health Network, Toronto, Ontario, Canada.
  • Langstein J; Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts.
  • Ekram MB; Princess Margaret Cancer Centre/University Health Network, Toronto, Ontario, Canada.
  • Li B; German Cancer Research Center, DKFZ, Heidelberg, Germany.
  • Davicioni E; Department of Medical Oncology, The Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston, Massachusetts.
  • Takhar M; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
  • Erho N; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Karnes RJ; Princess Margaret Cancer Centre/University Health Network, Toronto, Ontario, Canada.
  • Chadwick D; Research & Development, GenomeDx Biosciences Inc., Vancouver BC, Canada.
  • van der Kwast T; Research & Development, GenomeDx Biosciences Inc., Vancouver BC, Canada.
  • Boutros PC; Research & Development, GenomeDx Biosciences Inc., Vancouver BC, Canada.
  • Arrowsmith CH; Department of Urology, Mayo Clinic, Rochester, Minnesota.
  • Feng FY; UHN Program in BioSpecimen Sciences, Department of Pathology, University Health Network, Toronto, Ontario, Canada.
  • Joshua AM; Department of Pathology and Laboratory Medicine, Toronto General Hospital/University Health Network, Toronto, Canada.
  • Zoubeidi A; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
  • Cai C; Informatics and Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • He HH; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Cancer Res ; 77(20): 5479-5490, 2017 10 15.
Article in En | MEDLINE | ID: mdl-28916652
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Chromosomal Proteins, Non-Histone / Histone Demethylases / Prostatic Neoplasms, Castration-Resistant Limits: Animals / Humans / Male Language: En Journal: Cancer Res Year: 2017 Document type: Article Affiliation country: Canada Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Chromosomal Proteins, Non-Histone / Histone Demethylases / Prostatic Neoplasms, Castration-Resistant Limits: Animals / Humans / Male Language: En Journal: Cancer Res Year: 2017 Document type: Article Affiliation country: Canada Country of publication: United States